Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Difference
    0.2%
    Check dated 2025-05-08T10:31:42.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated to a new version, v2.15.2, indicating a revision in the content. However, there are no significant changes to core content, names, pricing, or availability.
    Difference
    0.3%
    Check dated 2025-05-01T05:28:48.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed descriptions of a Phase 1/2 study for the RET inhibitor BLU-667, which included key inclusion and exclusion criteria for participants with various cancers. Additionally, new terminology related to cancer types and a registry identifier have been added.
    Difference
    31%
    Check dated 2025-04-16T14:40:21.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-09T09:50:23.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.4%
    Check dated 2025-04-01T23:34:24.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The page now indicates that results have been submitted, replacing the previous message that no results were posted.
    Difference
    0.1%
    Check dated 2025-03-25T14:08:06.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.